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Abstract
 .A cDNA for a thromboxane A TXA receptor was cloned from an SV40 transformed African Green Monkey kidney2 2
 .cell line COS-7 . The sequence is 98% homologous with the isoform of the human TXA receptor and has agonist and2
antagonist ligand binding characteristics that are not significantly different from the human receptor. Stimulation of the
COS-7 cells with the TXA receptor agonist, ONO 11113 resulted in a significant increase in cAMP formation that was2
blocked by a receptor antagonist. The results raise the question of the utility of the COS-7 cell line for studies of cloned and
expressed TXA receptor signalling mechanisms. q 1998 Elsevier Science B.V. All rights reserved.2
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1. Introduction
 .Thromboxane A TXA receptors have been2 2
w x w xcloned from human placenta 1 , K562 cells 2 , HEL
w x w x w xcells 3 , endothelial cells 4 , mouse lung 5 rat
w x w xkidney 6 and rat astrocytes 7 . The cloned receptor
has been expressed in several lines, including
w x w x w xHEK293 cells 2,8,9 , CHO cells 4,10 , COS-1 5 ,
w x w xCOS m-6 10 and COS-7 cells 3,6,11 . It has been
assumed that the TXA receptor is not constitutively2
expressed in these cell lines, thus they could serve as
ideal cells in which to express and characterize the
cloned receptors. COS-7 cells are an SV40 trans-
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formed African Green monkey kidney cell line that
has been used extensively for the transient expression
of cloned receptors. However, it has been previously
demonstrated that there are TXA receptors present2
w xin the kidney of several mammalian species 6,12,13 .
During a routine study of a cloned human TXA 2
receptor expressed in COS-7 cells, we found an
increase in cAMP formation in response to a TXA 2
agonist in untransfected cells. This raised the possi-
bility that there may be a previously unrecognized
TXA receptor constitutively expressed in COS-72
cells.
2. Materials and methods
COS-7 cells were maintained in Dulbecco’s modi-
 .fied Eagles medium DMEM containing 10% Serum
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 .Plus JRH Biosciences. Lenexa, KS and 1% of a
solution containing 10 000 unitsrml penicillin G,
10 000 mgrml streptomycin, 25 mgrml amphoteri-
 .cin Gibco-BRL . Cells were grown at 378C with a
humidified atmosphere of 95% O and 5% CO . As2 2
there is a large variability in the clonality of this cell
line several sources of cells were maintained and
examined for these studies.
Total RNA was extracted from COS-7 cells grown
to confluence in three 100=20 mm culture dishes
 .with the TRIzol reagent Gibco-BRL . First strand
cDNA synthesis was carried out according to manu-
 .facturers recommendations. Total RNA 2 mg was
 .combined with 500 nM poly Aq -specific Adapter
 .Primer Gibco-BRL and sterile diethyl pyrocarbon-
 .ate-treated water 12 ml total vol. at 48C. The
RNArprimer mix was denatured at 708C for 10 min
 .and placed on ice. A mixture 7 ml that gave a final
 .reaction composition of 20 mM Tris–HCl pH 8.4 ,
50 mM KCl, 2.5 mM MgCl , 10 mM DTT and 5002
mM each dATP, dCTP, dGTP, dTTP was added and
the primers annealed at 428C for 5 min. Superscrip-
 .tase II 200 units reverse transcriptase was added
and the reaction continued for 60 min at 428C. The
enzyme was heat inactivated at 708C for 15 min. The
mRNA was degraded with 2 units RNase H at 378C
for 20 min.
X  .For 3 cDNA amplification, the poly- Aq spe-
X cific primers supplied with the 3 RACE kit Gibco-
.  .BRL , Universal Amplification Primer UAP and
 .Abridged Universal Amplification Primer AUAP
were utilized. All other primers were designed based
upon conserved regions of known TXA receptor2
w xisoforms 1,4,14 . The nucleotide numbers following
each primer sequence corresponds to their position in
 .the placental alpha isoform sequence. This includes
all except the antisense GSPB which was based upon
the 3X UTR of the COS-7 cell TXA receptor clone.2
P584 5X-GGAGCCATGTGGCCCAATGGC-3X,
nt. y6 toq15;
GSPA 5X-CACAAACATTACCCTGGAGGA-3X,
nt. q42 to q62;
P533 5X-GTCTTCATCGCCCAGACAGTG-3X,
nt. q754 to q774;
GSP2 5X-GTCTTCATCGCCCAGACAGTG-3X,
nt. q787 to q807;
GSPB 5X-ACGCGCGGGAGGGTGTGCTCT-3X,
nt. q1062 to q1042.
 .First strand cDNA reaction 1 ml was used as tem-
plate in the first round of PCR amplification Ericomp,
.San Diego, CA . Utilizing a nested primer approach,
the first round amplification products were diluted
1:20 in sterile dH O and used as template for the2
second round of amplification. The final PCR reac-
tion composition consisted of 5% DMSO, 200 nM of
each primer, 200 mM each deoxynucleotide, 1.5 mM
MgCl , 2.5 units of Taq polymerase.2
For both PCR amplification and 3X RACE, the hot
start method was employed. All reagents were assem-
bled on ice and placed directly into the preheated
cycler. Amplification was as follows; 988C for 5 min,
758C for 1-min addition of Taq polymerase, 30 cycles
of 948C for 1 min, 578C for 1 min, 728C for 3 min
and 1 cycle 728C for 15 min.
All amplification products to be sequenced were
gel-isolated in a 1.2% agarose gel, excised, purified
and extracted with phenol-chloroform and ethanol
precipitated. Sequencing was accomplished via the
dideoxy-chain termination fluorescence-based se-
quencing method MUSC: Nucleic Acid Analysis
.Facility . Two separate full length clones were se-
quenced in both the sense and antisense directions to
rule out PCR artifacts and confirm the sequence.
Fig. 1. Products from PCR using the primers 584 and GSPB and
the first strand cDNA. Lane A smolecular weight markers, lanes
B and CsPCR products. The resulting product was 1100 bp.
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Table 1
Sequence alignment for cloned thromboxane A receptors2
The numbers over the bars refer to the transmembrane domains. The bolded amino acids that are in the underlined column depict the
changed amino acid compared to the human isoform. The boxed areas depict the conserved regions across all the species.
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Sequence data were analyzed with DNA Strider soft-
ware and the NIH Genbank was used for the data-
bank searches. The sequence has been submitted to
Genbank and has the accession aAF017452.
Initially a 3X RACE-nested primer approach was
undertaken to specifically elucidate the carboxy ter-
minal end of the COS-7 TXA receptor, since this2
represents the area of divergence between the two
isoforms. First round 3X RACE with primers P584
and UAP produced several bands identified upon
 .electrophoresis. An aliquot 1 ml of the first round
 .product diluted 1:20 was then used as the template
for second round amplification. Second round primers
GSP2 and UAP produced a single 1200 bp band
identified upon electrophoresis. This product was se-
quenced and shown to encode the 3X end of an a-like
isoform of the TXA receptor with approximately2
700 bp of 3X UTR.
Based upon the 3X RACE results, a 3X UTR COS-7
 .cell gene-specific primer was designed GSPB . In
w xcombination with P584 3 which was designed based
on the 5X end of known isoforms of the receptor, the
 .full length clone was amplified Fig. 1 . The resulting
1100 bp fragment was sequenced and shown to en-
code a cDNA with an open reading frame of 1029 bp
 .and a deduced amino acid sequence of 343 Table 1 .
The COS-7 cell TXA receptor is 98% homologous2
with the amino acid sequence of the human isoform.
It differs from the known TXA alpha-isoform by 82
 .amino acids Table 1 . The majority of these amino
acid changes are conserved across other species
 .mouse, rat and cow . Of the 8 amino acids that differ
from the human isoform of the TXA receptor they2
are all conservative changes except at position 288
where the basic amino acid lysine has been changed
 .to the acidic amino acid glutamine Table 1 . The two
amino acid changes in the second intracellular loop
do not appear to have any effects on receptor effector
coupling, since stimulation of the receptor with ONO
11113 resulted in increased cAMP formation vide
.infra .
COS-7 cells grown to confluence were washed
with warm PBS and scraped into ice-cold incubation
 .buffer containing 25 mM HEPES pH 6.5 , 150 mM
NaCl, 10 mM MgCl and 5 mM KCl, 10 mM2
indomethacin, 0.01 M benzamidine and PMSF at a
concentration of 128 mgrml and a crude membrane
preparation was prepared using previously described
w xmethods 3 . Membrane proteins were quantitated
using a Bio-Rad protein assay system Hercules,
.CA .
Radioligand binding studies were performed with
25 mg of membrane proteinrassay in a final volume
w xof 200 ml as previously described 3 . Briefly, ho-
 .mogenized COS-7 cell membrane proteins 25 mg
 .were suspended in 25 mM HEPES pH 6.5 or 7.4 ,
150 mM NaCl, 10 mM MgCl and 5 mM KCl.2125 w w  .  . xx wI-BOP 1S- 1a , 2a Z , 3b 1E, 3S) , 4a -7- 3-
w w x x3-hydroxy-4- -4-iodophenoxy -1-butenyl -7-oxabicy-
w x x . w xclo 2.2.1 hept-2-yl -5-heptenoic acid 15 was added
at a concentration of 25 000 to 50 000 cpmrtube. All
components were combined on ice and incubated at
308C for 1 h. For the calculation of binding affinities
 .and receptor density B , data were analyzed ac-max
w xcording to the method of Scatchard 16 using the
w xLigand computer program 17 . Statistical analyses
were performed using StatWorks software Cricket
.Software, Philadelphia, PA . The data were analyzed
with Student’s t-test.
3. Discussion
Since the TXA receptor is constitutively ex-2
pressed, albeit at low levels, the ligand binding stud-
ies were carried out with membranes prepared from
untransfected cells. Several sources of COS-7 cells
were studied to confirm expression and binding of
the endogenous TXA receptors and to rule out2
variability among clonal subpopulations of this com-
mon cell line. All lines studied expressed the TXA 2
receptor. The COS-7 cell line expressed a TXA 2
receptor with an affinity for the agonist I-BOP of
1.6"0.3 nM and a B of 0.5"0.10 pmolrmgmax
 .membrane protein ns6 . This K value is veryd
similar to that of the cloned a and b isoforms of the
human TXA receptors. Preliminary data also re-2
vealed the presence of the receptor in COS-1 cells
but not in the embryonic kidney cell line, HEK 293,
 .or CHO cells unpublished observations . The low
density of receptors in the COS-7 cells is similar to
w xthat seen in vascular smooth muscle cells 18,19 .
Since, cloned TXA receptors have been overex-2
pressed in these cells in the past, the amount of
protein usually used in the binding assays would not
normally result in significant specific binding and
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thus would not lead to the notion that the receptor is
being expressed. The availability of an 125I-labelled
ligand, made it easy to determine the presence of
specific binding and thus lead to the cloning of the
receptor cDNA. Several of the previous studies em-
ployed a 3H-labelled ligand, thus the presence of the
receptors would not have been detected, since the
 .amount of protein 1–2.5 mg used when the recep-
tors are overexpressed would be too low to detect the
w xconstitutive expression 6,11 .
In an effort to determine if the differences in the
amino acid sequence of the receptor influenced lig-
and recognition, competition binding assays were
conducted with the stereoisomeric TXA receptor2
 . antagonist y L657925 gift from Merck-Frosst
.Canada, Point Claire-Dorval, Quebec, Canada which
has been used to demonstrate that the ligand binding
 .is to TXA receptors. The IC value for y L6579252 50
 .was 1.7"0.4 nM ns3 , which also very similar to
the value obtained for the cloned a and b isoforms
of the human TXA receptors.2
The human a isoform of the TXA receptor has2
been shown to signal via increases in cAMP forma-
w xtion 10,20 . To investigate the coupling of this recep-
tor to adenylyl cyclase, COS-7 cells were stimulated
 .with ONO 11113 gift from ONO Pharmaceutical
and the increase in cAMP quantitated via radioim-
munoassay. The primary antibody was kindly sup-
plied by Dr. T. Gettys Medical University of South
.Carolina, Charleston, SC . The secondary antibody
was a Goat-anti-rabbit from PerSpective Diagnostics
 . 125Cambridge, MA . I-cAMP was purchased from
 .Linco St. Charles, KS . Briefly, COS-7 cells were
grown in 100= 20 mm dishes until confluent,
trypsinized, resuspended in 10 ml DMEM with 10%
Serum Plus containing 1% antibiotic–antimycotic
mixture and 1 ml aliquots were transferred to 12 well
plates. The cells were incubated overnight, washed 2
times with warm PBS containing 10 mM indo-
methacin, and pretreated with 1 mM IBMX in DMEM
with no Serum Plus for 10 min at 378C. The cells
were stimulated for 3 min with the agonist ONO
11113" the TXA receptor antagonist, SQ295482
gift from Bristol–Meyers–Squibb Medical Research
.Institute . The supernatant was removed and the sam-
ples extracted with 0.5 ml of 0.1 N HCl. An aliquot
 .100 ml of the extracted sample was then used for
 .the acetylation reaction. An aliquot 50 ml of the
acetylated sample was assayed for cAMP. The basal
level of cAMP in COS-7 cells was 6.4 " 2.1
pmolrwell and increased to a level of 28.9"11.3
 .pmolrwell with 1 mM ONO 11113 ns3 . This
represented a 4.4"0.3-fold increase in cAMP p-
.0.04 . Pre-treatment for 10 min with the TXA re-2
 .ceptor antagonist SQ29,548 10 mM reduced the
response to ONO 11113 to 15.9"10.3 pmolrwell
 . ns3 . In a second series of experiments ns3 to
.4 , the basal level of cAMP was 4.0"0.8 pmolrwell
and increased to 4.9"0.9 pmolrwell for I-BOP 0.1
.  .mM and 4.2"1 pmolrwell for I-BOP 1 mM .
 .Preincubation of the cells with SQ29,548 25 mM
 .reduced the response to I-BOP 0.1 mM and I-BOP
 .1 mM to 3.7"0.9 and 3.0"0.9 pmolrwell, re-
spectively.
The cloning of the COS-7 cell TXA receptor is2
of particular importance since this cell line represents
a common system used to investigate the signal
transduction pathways of many G-protein-coupled re-
ceptors including TXA receptors. Thus, studies of2
TXA receptors and their signalling mechanisms in2
COS-7 cells should be interpreted with caution.
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